139 related articles for article (PubMed ID: 16313478)
1. Effects of 17beta-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women.
Tankó LB; Christiansen C
J Intern Med; 2005 Dec; 258(6):544-53. PubMed ID: 16313478
[TBL] [Abstract][Full Text] [Related]
2. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension.
White WB; Pitt B; Preston RA; Hanes V
Circulation; 2005 Sep; 112(13):1979-84. PubMed ID: 16186434
[TBL] [Abstract][Full Text] [Related]
3. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide.
Preston RA; Norris PM; Alonso AB; Ni P; Hanes V; Karara AH
Menopause; 2007; 14(3 Pt 1):408-14. PubMed ID: 17224857
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
Archer DF; Thorneycroft IH; Foegh M; Hanes V; Glant MD; Bitterman P; Kempson RL
Menopause; 2005; 12(6):716-27. PubMed ID: 16278615
[TBL] [Abstract][Full Text] [Related]
5. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women.
Preston RA; White WB; Pitt B; Bakris G; Norris PM; Hanes V
Am J Hypertens; 2005 Jun; 18(6):797-804. PubMed ID: 15925739
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study.
Lee BS; Kang BM; Yoon BK; Choi H; Park HM; Kim JG
Maturitas; 2007 Aug; 57(4):361-9. PubMed ID: 17467203
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women.
Karara AH; Hanes V; Alonso A; Ni P; Poola N; Silang R; Blode H; Preston RA
J Clin Pharmacol; 2007 Oct; 47(10):1292-302. PubMed ID: 17906162
[TBL] [Abstract][Full Text] [Related]
8. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate.
Junge W; El-Samalouti V; Gerlinger C; Schaefers M
Eur J Obstet Gynecol Reprod Biol; 2009 Dec; 147(2):195-200. PubMed ID: 19879683
[TBL] [Abstract][Full Text] [Related]
9. Effect of 6 months of exercise and isoflavone supplementation on clinical cardiovascular risk factors in obese postmenopausal women: a randomized, double-blind study.
Aubertin-Leheudre M; Lord C; Khalil A; Dionne IJ
Menopause; 2007; 14(4):624-9. PubMed ID: 17290158
[TBL] [Abstract][Full Text] [Related]
10. Serum adiponectin concentration and cardiovascular risk factors in climacteric women.
Milewicz A; Zatonska K; Demissie M; Jêdrzejuk D; Dunajska K; Ilow R; Lwow F
Gynecol Endocrinol; 2005 Feb; 20(2):68-73. PubMed ID: 15823824
[TBL] [Abstract][Full Text] [Related]
11. Effects of drospirenone/estrogen combinations on bone metabolism.
Christiansen C
Climacteric; 2005 Oct; 8 Suppl 3():35-41. PubMed ID: 16203654
[TBL] [Abstract][Full Text] [Related]
12. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women.
Lin SQ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Zhou YZ; Wang ML; Zhu J; Chen SR; Su H; Yang CS; Wang SH; Zhang YZ; Dong XJ
Climacteric; 2011 Aug; 14(4):472-81. PubMed ID: 21469973
[TBL] [Abstract][Full Text] [Related]
13. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
Oelkers WH
Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
[TBL] [Abstract][Full Text] [Related]
14. Added benefits of drospirenone for compliance.
Foidart JM
Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
[TBL] [Abstract][Full Text] [Related]
15. The effects of 17β-estradiol plus drospirenone on anthropometric and biochemical measures of adiposity in menopausal women.
Karakus M; Gelisgen R; Topcuoglu A; Guralp O; Topcuoglu D; Simsek G; Uludag S; Uzun H
Arch Gynecol Obstet; 2012 Nov; 286(5):1233-9. PubMed ID: 22791413
[TBL] [Abstract][Full Text] [Related]
16. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension.
White WB; Hanes V; Chauhan V; Pitt B
Hypertension; 2006 Aug; 48(2):246-53. PubMed ID: 16801478
[TBL] [Abstract][Full Text] [Related]
17. Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women.
Godsland IF; Manassiev NA; Felton CV; Proudler AJ; Crook D; Whitehead MI; Stevenson JC
Clin Endocrinol (Oxf); 2004 May; 60(5):541-9. PubMed ID: 15104556
[TBL] [Abstract][Full Text] [Related]
18. Adipose tissue, insulin resistance and low-grade inflammation: implications for atherogenesis and the cardiovascular harm of estrogen plus progestogen therapy.
Tankó LB; Christiansen C
Climacteric; 2006 Jun; 9(3):169-80. PubMed ID: 16766431
[TBL] [Abstract][Full Text] [Related]
19. Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris.
Knuuti J; Kalliokoski R; Janatuinen T; Hannukainen J; Kalliokoski KK; Koskenvuo J; Lundt S
Am J Cardiol; 2007 Jun; 99(12):1648-52. PubMed ID: 17560868
[TBL] [Abstract][Full Text] [Related]
20. Effects of nonoral estradiol-micronized progesterone or low-dose oral estradiol-drospirenone therapy on metabolic variables and markers of endothelial function in early postmenopause.
Casanova G; Radavelli S; Lhullier F; Spritzer PM
Fertil Steril; 2009 Aug; 92(2):605-12. PubMed ID: 18706557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
